Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash ...
Immatics has innovative TCR therapies, strong cash position, and expanding clinical pipeline targeting solid tumors. Read for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback